It’s time to rethink clinical trials in a post-pandemic world

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Becky Stephens is more than willing to go to great lengths for a miracle. With a diagnosis of stage 4 colon cancer and chemo treatments that weren’t working, she was desperate for hope—and found it in a clinical trial. 

So, the mother of three started making the often, four-hour round-trip trek from Santa Rosa to UCSF Medical Center every two weeks to participate. But the travel was tough. Aside from the cancer treatment leaving her exhausted, the long car trips were wearing on her. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Dana Dornsife
Founder and CEO, Lazarex Cancer Foundation
Table of Contents

YOU MAY BE INTERESTED IN

In this week's episode of The Cancer Letter Podcast, editor and publisher Paul Goldberg, and associate editor Jacquelyn Cobb revisit two of last week’s most-read stories: the growing recognition that early-onset colorectal cancer requires a new diagnostic mindset, and the life and legacy of Maura Gillison, the scientist whose discovery that most head and neck cancers are driven by HPV transformed the field. 
For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.
Dana Dornsife
Founder and CEO, Lazarex Cancer Foundation

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login